November 6, 2025 (Washington, DC) — In response to the Trump administration’s announcement to expand access to obesity management medications within the Medicare and Medicaid programs, Alliance for Women’s Health & Prevention (AWHP) CEO Millicent Gorham issued the following statement:  

“Today’s announcement from the White House is a meaningful and positive step towards improving access to care for many people living with obesity,” said Millicent Gorham, CEO of AWHP.

“Obesity is a complex chronic disease associated with over 200 health complications, including many that specifically affect women, such as breast and ovarian cancers. Research shows that patient-centered obesity care must leverage the full continuum of evidence-based interventions, including FDA-approved medications. By doing so, we can address the economic and societal burden of chronic disease plaguing our country.

I have heard firsthand from women living with obesity how access to care can be life changing. That should be the reality for all Americans living with this disease. While this initiative is a positive development that will improve access to FDA-approved obesity management medications, more work remains to ensure that everyone living with obesity has coverage for needed care. AWHP will continue to work with policymakers, employers and private health insurers to build on this momentum.”